{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:29:51Z","timestamp":1783531791080,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Autologous hematopoietic stem cell transplantation (AHSCT) has been increasingly used for treatment of relapsing-remitting multiple sclerosis (RRMS). Existing data suggest that AHSCT might alter the natural course of multiple sclerosis (MS) and postpone or even prevent the occurrence of progressive MS. This study aimed to investigate whether three cerebrospinal fluid biomarkers of progressive MS: Galectin-9, GDF-15, and YKL-40, were affected by treatment intervention with AHSCT for RRMS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>RRMS patients treated with AHSCT at Uppsala University Hospital between 2011 and 2018 were considered for participation and included if CSF samples from baseline and at least one follow-up were available. CSF from healthy volunteers was included as controls. Galectin-9 and GDF-15 concentrations were determined with ELISA, and YKL-40 with electrochemiluminescence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The final cohort comprised 45 RRMS patients and 32 controls. At baseline, MS patients had markedly higher CSF concentrations of Galectin-9 and YKL-40 and slightly higher GDF-15 than controls. Following AHSCT, biomarker concentrations decreased from baseline to the 1-year follow-up, with a median (IQR) of 454 (357\u2013553) vs. 408 (328\u2013495) pg\/mL (<jats:italic>P<\/jats:italic>\u2009=\u20090.0002) for Galectin-9; 49 (38\u201379) vs. 45 (35 to 75) pg\/mL (<jats:italic>P<\/jats:italic>\u2009=\u20090.012) for GDF-15, and 100 (54\u2013164) vs. 58 (43\u201392) ng\/mL (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) for YKL-40. Galectin-9 and YKL-40 concentrations decreased further and were even lower at the 2-year follow-up; median (IQR) 408 (328\u2013495) vs. 376 (289\u2013478) pg\/mL (<jats:italic>P<\/jats:italic>\u2009=\u20090.0009) for Galectin-9; and 62 (37\u201396) vs. 56 (30\u201383) ng\/mL (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) for YKL-40. Thereafter, the levels of all biomarkers were stable throughout the follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Treatment with AHSCT was associated with sustained reductions in biomarkers linked to progressive MS, indicating its potential not only to achieve lasting remission but also to delay or prevent transition to SPMS. However, additional studies are necessary to confirm these findings and elucidate their long-term clinical significance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12974-025-03511-6","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T18:46:02Z","timestamp":1752777962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Biomarkers of progressive multiple sclerosis decrease following autologous hematopoietic stem cell transplantation"],"prefix":"10.1186","volume":"22","author":[{"given":"Ida","family":"Erngren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Lundblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Al-Grety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kultima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"2","key":"3511_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","volume":"78","author":"AE Miller","year":"2021","unstructured":"Miller AE, Chitnis T, Cohen BA, Costello K, Sicotte NL, Stacom R, et al. Autologous hematopoietic stem cell transplant in multiple sclerosis. JAMA Neurol. 2021;78(2):241.","journal-title":"JAMA Neurol"},{"key":"3511_CR2","doi-asserted-by":"crossref","unstructured":"for the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE), Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplant. 2020;55(2):283\u2013306.","DOI":"10.1038\/s41409-019-0684-0"},{"issue":"2","key":"3511_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/jnnp-2023-331864","volume":"95","author":"T Silfverberg","year":"2024","unstructured":"Silfverberg T, Zjukovskaja C, Ljungman P, Nahimi A, Ahlstrand E, Dreimane A, et al. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in sweden: an observational cohort study. J Neurol Neurosurg Psychiatry. 2024;95(2):125\u201333.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"3511_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","volume":"84","author":"GL Mancardi","year":"2015","unstructured":"Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2015;84(10):981\u20138.","journal-title":"Neurology"},{"issue":"2","key":"3511_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2018.18743","volume":"321","author":"RK Burt","year":"2019","unstructured":"Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-Modifying therapy on disease progression in patients with Relapsing-Remitting multiple sclerosis: A randomized clinical trial. JAMA. 2019;321(2):165\u201374.","journal-title":"JAMA"},{"issue":"3","key":"3511_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molmed.2013.11.007","volume":"20","author":"ME Witte","year":"2014","unstructured":"Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med. 2014;20(3):179\u201387.","journal-title":"Trends Mol Med"},{"issue":"2","key":"3511_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","volume":"14","author":"DH Mahad","year":"2015","unstructured":"Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183\u201393.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3511_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","volume":"76","author":"SH Barondes","year":"1994","unstructured":"Barondes SH, Castronovo V, Cooper DNW, Cummings RD, Drickamer K, Felzi T, et al. Galectins: A family of animal \u03b2-galactoside-binding lectins. Cell. 1994;76(4):597\u20138.","journal-title":"Cell"},{"issue":"9","key":"3511_CR9","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1074\/jbc.272.9.6078","volume":"272","author":"J Wada","year":"1997","unstructured":"Wada J, Kanwar YS. Identification and characterization of galectin-9, a novel \u03b2-galactoside-binding mammalian lectin. J Biol Chem. 1997;272(9):6078\u201386.","journal-title":"J Biol Chem"},{"issue":"1","key":"3511_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clim.2008.01.006","volume":"127","author":"M Seki","year":"2008","unstructured":"Seki M, Oomizu S, Sakata K-M, Sakata A, Arikawa T, Watanabe K, et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 2008;127(1):78\u201388.","journal-title":"Clin Immunol"},{"issue":"12","key":"3511_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6(12):1245\u201352.","journal-title":"Nat Immunol"},{"issue":"11","key":"3511_CR12","doi-asserted-by":"publisher","first-page":"e48574","DOI":"10.1371\/journal.pone.0048574","volume":"7","author":"S Oomizu","year":"2012","unstructured":"Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, et al. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3 + Treg development by galectin-9 secretion. PLoS ONE. 2012;7(11):e48574.","journal-title":"PLoS ONE"},{"issue":"5853","key":"3511_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1126\/science.1148536","volume":"318","author":"AC Anderson","year":"2007","unstructured":"Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141\u20133.","journal-title":"Science"},{"key":"3511_CR14","doi-asserted-by":"publisher","unstructured":"Steelman AJ, Li J. Astrocyte galectin-9 potentiates microglial TNF secretion. J Neuroinflammation [Internet]. 2014;11(1). Available from: https:\/\/doi.org\/10.1186\/s12974-014-0144-0","DOI":"10.1186\/s12974-014-0144-0"},{"issue":"33","key":"3511_CR15","doi-asserted-by":"publisher","first-page":"23776","DOI":"10.1074\/jbc.M113.451658","volume":"288","author":"AJ Steelman","year":"2013","unstructured":"Steelman AJ, Smith R 3rd, Welsh CJ, Li J. Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J Biol Chem. 2013;288(33):23776\u201387.","journal-title":"J Biol Chem"},{"key":"3511_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jneuroim.2016.01.008","volume":"292","author":"J Burman","year":"2016","unstructured":"Burman J, Svenningsson A. Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. J Neuroimmunol. 2016;292:40\u20134.","journal-title":"J Neuroimmunol"},{"issue":"21","key":"3511_CR17","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","volume":"94","author":"MR Bootcov","year":"1997","unstructured":"Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-\u03b2 superfamily. Proc Natl Acad Sci U S A. 1997;94(21):11514\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"3511_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/08977194.2011.607137","volume":"29","author":"SN Breit","year":"2011","unstructured":"Breit SN, Johnen H, Cook AD, Tsai VWW, Mohammad MG, Kuffner T, et al. The TGF-\u03b2 superfamily cytokine, MIC-1\/GDF15: A pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors. 2011;29(5):187\u201395.","journal-title":"Growth Factors"},{"issue":"5","key":"3511_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10408363.2019.1615034","volume":"56","author":"S Desmedt","year":"2019","unstructured":"Desmedt S, Desmedt V, De Vos L, Delanghe JR, Speeckaert R, Speeckaert MM. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit Rev Clin Lab Sci. 2019;56(5):333\u201350.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"3511_CR20","doi-asserted-by":"publisher","first-page":"e2502","DOI":"10.1002\/brb3.2502","volume":"12","author":"X-H Xue","year":"2022","unstructured":"Xue X-H, Tao L-L, Su D-Q, Guo C-J, Liu H. Diagnostic utility of GDF15 in neurodegenerative diseases: A systematic review and meta-analysis. Brain Behav. 2022;12(2):e2502.","journal-title":"Brain Behav"},{"issue":"102434","key":"3511_CR21","doi-asserted-by":"publisher","first-page":"102434","DOI":"10.1016\/j.msard.2020.102434","volume":"45","author":"P Kosa","year":"2020","unstructured":"Kosa P, Wu T, Phillips J, Leinonen M, Masvekar R, Komori M, et al. Idebenone does not inhibit disability progression in primary progressive MS. Mult Scler Relat Disord. 2020;45(102434):102434.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"3511_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1742-2094-7-34","volume":"7","author":"D Bonneh-Barkay","year":"2010","unstructured":"Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010;7(1):34.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"3511_CR23","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/brain\/awv017","volume":"138","author":"E Cant\u00f3","year":"2015","unstructured":"Cant\u00f3 E, Tintor\u00e9 M, Villar LM, Costa C, Nurtdinov R, \u00c1lvarez-Cerme\u00f1o JC, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015;138(4):918\u201331.","journal-title":"Brain"},{"issue":"6","key":"3511_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/revneuro-2020-0145","volume":"32","author":"S Momtazmanesh","year":"2021","unstructured":"Momtazmanesh S, Shobeiri P, Saghazadeh A, Teunissen CE, Burman J, Szalardy L, et al. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. Rev Neurosci. 2021;32(6):573\u201395.","journal-title":"Rev Neurosci"},{"key":"3511_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jneuroim.2016.08.004","volume":"299","author":"MA Ma\u00f1\u00e9-Mart\u00ednez","year":"2016","unstructured":"Ma\u00f1\u00e9-Mart\u00ednez MA, Olsson B, Bau L, Matas E, Cobo-Calvo \u00c1, Andreasson U, et al. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. J Neuroimmunol. 2016;299:112\u20137.","journal-title":"J Neuroimmunol"},{"key":"3511_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jneuroim.2016.01.013","volume":"292","author":"J Burman","year":"2016","unstructured":"Burman J, Raininko R, Blennow K, Zetterberg H, Axelsson M, Malmestr\u00f6m C. YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol. 2016;292:52\u20137.","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"3511_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2014.02.004","volume":"269","author":"C Malmestr\u00f6m","year":"2014","unstructured":"Malmestr\u00f6m C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B. CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment. J Neuroimmunol. 2014;269(1\u20132):87\u20139.","journal-title":"J Neuroimmunol"},{"issue":"2","key":"3511_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"22","key":"3511_CR29","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914\u201322.","journal-title":"Neurology"},{"issue":"16","key":"3511_CR30","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.7150\/thno.26249","volume":"8","author":"S Herman","year":"2018","unstructured":"Herman S, Khoonsari PE, Tolf A, Steinmetz J, Zetterberg H, \u00c5kerfeldt T, et al. Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis. Theranostics. 2018;8(16):4477\u201390.","journal-title":"Theranostics"},{"issue":"3","key":"3511_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1212\/WNL.53.3.457","volume":"53","author":"TNF neutralization in MS","year":"1999","unstructured":"TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology. 1999;53(3):457\u2013457.","journal-title":"Neurology"},{"key":"3511_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fneur.2015.00180","volume":"6","author":"J Correale","year":"2015","unstructured":"Correale J, Farez MF. The role of astrocytes in multiple sclerosis progression. Front Neurol. 2015;6:180.","journal-title":"Front Neurol"},{"issue":"2","key":"3511_CR33","doi-asserted-by":"publisher","first-page":"e0148709","DOI":"10.1371\/journal.pone.0148709","volume":"11","author":"R Montero","year":"2016","unstructured":"Montero R, Yubero D, Villarroya J, Henares D, Jou C, Rodr\u00edguez MA, et al. GDF-15 is elevated in children with mitochondrial diseases and is induced by mitochondrial dysfunction. PLoS ONE. 2016;11(2):e0148709.","journal-title":"PLoS ONE"},{"issue":"5","key":"3511_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.24506","volume":"78","author":"S Yatsuga","year":"2015","unstructured":"Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015;78(5):814\u201323.","journal-title":"Ann Neurol"},{"key":"3511_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2019.10.005","volume":"50","author":"NS Poulsen","year":"2020","unstructured":"Poulsen NS, Madsen KL, Hornsyld TM, Eisum A-SV, Fornander F, Buch AE, et al. Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy. Mitochondrion. 2020;50:35\u201341.","journal-title":"Mitochondrion"},{"key":"3511_CR36","doi-asserted-by":"publisher","unstructured":"Cross AH, Gelfand JM, Thebault S, Bennett JL, von B\u00fcdingen HC, Cameron B et al. Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis. JAMA Neurol [Internet]. 2024; Available from: https:\/\/doi.org\/10.1001\/jamaneurol.2024.0017","DOI":"10.1001\/jamaneurol.2024.0017"},{"issue":"8","key":"3511_CR37","doi-asserted-by":"publisher","first-page":"e1215","DOI":"10.1212\/WNL.0000000000011461","volume":"96","author":"G Boffa","year":"2021","unstructured":"Boffa G, Massacesi L, Inglese M, Mariottini A, Capobianco M, Moiola L, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2021;96(8):e1215\u201326.","journal-title":"Neurology"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03511-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03511-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:37:18Z","timestamp":1757252238000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-025-03511-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3511"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03511-6","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Ethical Review Board in Uppsala (Dnr 2008\/182, 2010\/450\/1 and 2012\/080\/1). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}